A clinical trial using transgenic herpes simplex virus type 1 (Talimogene laherparepvec) in combination with pembrolizumab in patients with advanced melanoma showed that OVs might make tumor cells more sensitive to immune checkpoint inhibitors by up-regulating PD-L1 expression (64). Here, CD274 is linked to neoplasm.